AR085984A1 - Moleculas de union biespecificas que se unen al factor de crecimiento endotelial (vegf) y a la angiopoyetina 2 (ang2) - Google Patents
Moleculas de union biespecificas que se unen al factor de crecimiento endotelial (vegf) y a la angiopoyetina 2 (ang2)Info
- Publication number
- AR085984A1 AR085984A1 ARP120101130A ARP120101130A AR085984A1 AR 085984 A1 AR085984 A1 AR 085984A1 AR P120101130 A ARP120101130 A AR P120101130A AR P120101130 A ARP120101130 A AR P120101130A AR 085984 A1 AR085984 A1 AR 085984A1
- Authority
- AR
- Argentina
- Prior art keywords
- xaa
- ang2
- vegf
- binding component
- gly
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 6
- 239000003102 growth factor Substances 0.000 title 1
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 5
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 102100034594 Angiopoietin-1 Human genes 0.000 abstract 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 abstract 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 abstract 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 101100216078 Mus musculus Ang4 gene Proteins 0.000 abstract 1
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 abstract 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940027941 immunoglobulin g Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Moléculas de unión biespecíficas que se unen tanto a VEGF como a Ang2, preferiblemente en forma de dominios variables individuales de inmunoglobulina tales como inmunoglobulina G de dominio variable de cadena pesada (VHH) y anticuerpos de dominio, composiciones farmacéuticas que las contienen y su uso en el tratamiento de enfermedades que están asociadas con los efectos mediados por VEGF y/o Ang2 sobre la angiogénesis (tratamiento de enfermedades cancerosas y enfermedades oftálmicas). Además, también ácidos nucleicos que codifican moléculas de unión biespecíficas, células huésped y métodos para prepararlos.Reivindicación 1: Una molécula de unión biespecífica caracterizada porque comprende al menos un componente de unión a VEGF, al menos un componente de unión a Ang2 y al menos un componente de unión de albúmina sérica, en la que dicho componente de unión a Ang2 se une con Ang2 con una potencia al menos 5.000 veces más alta que a Ang1 o a Ang4. Reivindicación 2: Una molécula de unión biespecífica de la reivindicación 1, caracterizada porque dicho componente de unión a VEGF comprende al menos un dominio variable con cuatro regiones marco y tres regiones determinantes de complementariedad CDR1, CDR2 y CDR3, respectivamente, en la que dicha CDR3 tiene la secuencia de aminoácidos Ser Arg Ala Tyr Xaa Ser Xaa Arg Leu Arg Leu Xaa Xaa Thr Tyr Xaa Tyr como se muestra en SEC ID Nº 1, en la que Xaa en la posición 5 es Gly o Ala; Xaa en la posición 7 es Ser o Gly; Xaa en la posición 12 es Gly, Ala o Pro; Xaa en la posición 13 es Asp o Gly; Xaa en la posición 16 es Asp o Glu; y en la que dicho componente de unión a VEGF es capaz de bloquear la interacción de VEGF165 recombinante humano con el VEGFR-2 recombinante humano con una tasa de inhibición de ³ 60%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160921 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085984A1 true AR085984A1 (es) | 2013-11-13 |
Family
ID=45895502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101130A AR085984A1 (es) | 2011-04-01 | 2012-03-30 | Moleculas de union biespecificas que se unen al factor de crecimiento endotelial (vegf) y a la angiopoyetina 2 (ang2) |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9527925B2 (es) |
| EP (2) | EP3144322A3 (es) |
| JP (2) | JP6023786B2 (es) |
| KR (1) | KR101907572B1 (es) |
| CN (2) | CN103562222B (es) |
| AP (1) | AP2013007085A0 (es) |
| AR (1) | AR085984A1 (es) |
| AU (2) | AU2012237234B2 (es) |
| BR (1) | BR112013025304B1 (es) |
| CA (1) | CA2827817C (es) |
| CL (1) | CL2013002623A1 (es) |
| CO (1) | CO6801639A2 (es) |
| CY (1) | CY1118339T1 (es) |
| DK (1) | DK2694546T3 (es) |
| EA (2) | EA036746B1 (es) |
| EC (1) | ECSP13013001A (es) |
| ES (1) | ES2606302T3 (es) |
| HK (1) | HK1225400A1 (es) |
| HR (1) | HRP20161689T1 (es) |
| HU (1) | HUE030148T2 (es) |
| IL (1) | IL227936B (es) |
| LT (1) | LT2694546T (es) |
| MA (1) | MA34979B1 (es) |
| MX (2) | MX343440B (es) |
| MY (1) | MY171007A (es) |
| PE (1) | PE20140448A1 (es) |
| PH (1) | PH12013502044A1 (es) |
| PL (1) | PL2694546T3 (es) |
| PT (1) | PT2694546T (es) |
| RS (1) | RS55361B1 (es) |
| SG (2) | SG193561A1 (es) |
| SI (1) | SI2694546T1 (es) |
| TN (1) | TN2013000390A1 (es) |
| UA (1) | UA114707C2 (es) |
| UY (1) | UY33998A (es) |
| WO (1) | WO2012131078A1 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| JP5970734B2 (ja) * | 2012-03-30 | 2016-08-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｎｇ２結合分子 |
| SMT202100621T1 (it) | 2012-07-13 | 2022-01-10 | Roche Glycart Ag | Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| KR20150060686A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| CA2968141C (en) * | 2015-01-16 | 2020-08-04 | Hsing-Mao CHU | Molecular constructs with targeting and effector elements |
| AR103477A1 (es) | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| IL254577B2 (en) | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | polypeptides |
| IL254589B2 (en) | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | A peptide structure with a protease-cleavable linker |
| CN107438620A (zh) * | 2015-03-31 | 2017-12-05 | 韦斯夸尔德有限公司 | 多肽 |
| PL3328886T3 (pl) * | 2015-07-29 | 2021-02-08 | Allergan, Inc. | Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu |
| HK1254093A1 (zh) | 2015-08-14 | 2019-07-12 | Allergan, Inc. | 仅有重链的pdgf抗体 |
| CA2992602A1 (en) * | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
| RS62857B1 (sr) * | 2015-11-13 | 2022-02-28 | Ablynx Nv | Unapređeni varijabilni domeni imunoglobulina koji vezuju serumski albumin |
| US10597449B2 (en) | 2015-12-04 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing Wnt signaling in tumor cells |
| IL264961B2 (en) | 2016-08-23 | 2025-02-01 | Medimmune Ltd | Antibodies against VEGF–A and their uses |
| US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
| EP4190318A1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| RU2648164C1 (ru) * | 2016-12-19 | 2018-03-22 | Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| MX2019014331A (es) | 2017-05-31 | 2020-01-27 | Boehringer Ingelheim Int | Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales. |
| CA3061053A1 (en) * | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| CN119733046A (zh) | 2018-02-06 | 2025-04-01 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| WO2019246273A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| JP2021529556A (ja) | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． | 抗腫瘍アンタゴニスト |
| MX2021004774A (es) | 2018-10-29 | 2021-08-24 | Hoffmann La Roche | Formulacion de anticuerpos. |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN114340735B (zh) | 2019-06-28 | 2024-11-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
| CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
| US20230032087A1 (en) * | 2019-12-11 | 2023-02-02 | Cullinan Oncology, Inc. | Anti-serum albumin antibodies |
| WO2021119551A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| WO2021155151A1 (en) * | 2020-01-29 | 2021-08-05 | The Methodist Hospital System | Multivalent ligands targeting cell surface receptors and force measurement platform for making the same |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| WO2022010271A1 (ko) | 2020-07-07 | 2022-01-13 | 주식회사 카나프테라퓨틱스 | 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도 |
| CN116507627B (zh) | 2020-11-02 | 2026-01-23 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| EP4019548A1 (en) * | 2020-12-23 | 2022-06-29 | Vrije Universiteit Brussel | Anti lag3 vhhs and their use |
| KR20230142838A (ko) * | 2021-02-10 | 2023-10-11 | 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 | 항-vegf 항체 및 이의 용도 |
| KR20230165901A (ko) * | 2021-02-19 | 2023-12-05 | 도트바이오 피티이. 리미티드 | Vegfa-결합 분자 |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| TW202302633A (zh) * | 2021-06-04 | 2023-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途 |
| EP4386004A4 (en) * | 2021-08-13 | 2025-08-13 | Innovent Biologics Suzhou Co Ltd | BISPECIFIC ANTI-VEGF A AND ANTI-VEGF C ANTIBODY AND ITS USE |
| MX2024002962A (es) * | 2021-09-10 | 2024-05-17 | Soter Biopharma Pte Ltd | Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo. |
| CU24770B1 (es) * | 2021-12-15 | 2025-09-01 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| WO2024055995A1 (zh) | 2022-09-14 | 2024-03-21 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合蛋白及其制备方法和应用 |
| EP4582447A4 (en) * | 2022-09-14 | 2026-01-21 | Quaerite Biopharm Res Beijing Co Ltd | ANTI-VEGFA ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THESE AND ITS USE |
| AU2023404729A1 (en) * | 2022-12-01 | 2025-06-26 | Innovent Biologics (Suzhou) Co., Ltd. | Trispecific fusion protein and use thereof |
| AU2023404529A1 (en) | 2022-12-01 | 2025-07-10 | Innovent Biologics (Suzhou) Co., Ltd. | Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof |
| WO2024178730A1 (zh) * | 2023-03-02 | 2024-09-06 | 清华大学 | 用于抑制脉络膜新生血管的玻璃体内抗vegf可结晶蛋白药物 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2025219504A1 (en) | 2024-04-19 | 2025-10-23 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420178T1 (de) | 1992-08-21 | 2009-01-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| US5408535A (en) | 1993-09-07 | 1995-04-18 | Miles Inc. | Video test strip reader and method for evaluating test strips |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| NZ500078A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| WO2001077137A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN1268394C (zh) | 2001-01-17 | 2006-08-09 | 特鲁比昂药品公司 | 结合域－免疫球蛋白融合蛋白 |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20040139501A1 (en) | 2002-03-01 | 2004-07-15 | Ball Horticultural Company | Lis promoter for expression of transgenes in floral tissues |
| JP2006515177A (ja) | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置 |
| JP2006520584A (ja) | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| US20050043220A1 (en) | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| WO2004062551A2 (en) | 2003-01-10 | 2004-07-29 | Ablynx N.V. | RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| EP3168304A1 (en) | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| DE60334645D1 (de) | 2003-11-07 | 2010-12-02 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| PE20061075A1 (es) | 2004-12-17 | 2006-11-15 | Genentech Inc | Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| EP3613767A1 (en) * | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| KR101414438B1 (ko) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체 |
| US8377398B2 (en) | 2005-05-31 | 2013-02-19 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to determination and use of white blood cell counts |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2006287228B2 (en) | 2005-09-01 | 2012-12-13 | Alora Biopharma, Inc. | Methods for using and identifying modulators of Delta-like 4 |
| WO2007043109A1 (ja) | 2005-09-30 | 2007-04-19 | Fujitsu Limited | 情報記憶装置 |
| KR101371773B1 (ko) * | 2005-12-15 | 2014-03-07 | 아스트라제네카 아베 | 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물 |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| JP2009523460A (ja) | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US7570881B2 (en) | 2006-02-21 | 2009-08-04 | Nokia Corporation | Color balanced camera with a flash light unit |
| US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2008060705A2 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| RU2008152435A (ru) | 2006-06-06 | 2010-07-20 | Дженентек, Инк. (Us) | Композиции и способы регулирования развития сосудов |
| CN101500605B (zh) | 2006-08-07 | 2014-04-30 | 瑞泽恩制药公司 | Dll4拮抗剂在治疗局部缺血性损伤中的用途 |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| CA2666511A1 (en) | 2006-10-11 | 2008-04-17 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof |
| US20110076279A1 (en) | 2006-10-20 | 2011-03-31 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CA2678218A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| MX2009010282A (es) * | 2007-03-29 | 2009-10-12 | Genmab As | Anticuerpos biespecificos y metodos para su produccion. |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| MX2009013137A (es) | 2007-06-06 | 2010-04-30 | Domantis Ltd | Metodos para seleccionar polipeptidos resistentes a la proteasa. |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| US8216571B2 (en) | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
| US9023351B2 (en) | 2007-11-26 | 2015-05-05 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses thereof |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| MY166446A (en) | 2008-03-18 | 2018-06-27 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use |
| CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| JP5809557B2 (ja) | 2008-06-05 | 2015-11-11 | アブリンクス エン．ヴェー． | ウイルスのエンベロープタンパク質に指向性を有するアミノ酸配列、及びウイルス疾患の治療のためのこれを含むポリペプチド |
| DK2307454T3 (en) | 2008-06-25 | 2017-04-24 | Esbatech Alcon Biomed Res Unit | Stable and soluble antibodies that inhibit VEGF |
| CA2734905A1 (en) | 2008-09-03 | 2010-03-11 | Jenny M. Bostrom | Multispecific antibodies |
| CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JP5823871B2 (ja) | 2008-12-10 | 2015-11-25 | アブリンクス エン．ヴェー． | 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| WO2010081219A1 (en) | 2009-01-13 | 2010-07-22 | Fio Corporation | A handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CN102482349B (zh) | 2009-06-17 | 2017-08-25 | 艾伯维生物医疗股份有限公司 | 抗vegf抗体和其用途 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| UY32920A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| UY32917A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| RU2012140447A (ru) | 2010-02-23 | 2014-03-27 | Дженентек, Инк. | Антиангиогенная терапия для лечения рака яичника |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| WO2012012499A1 (en) | 2010-07-20 | 2012-01-26 | Nurx Pharmaceuticals, Inc. | Optical reader system |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| JP2014500712A (ja) | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| CA2834373A1 (en) | 2011-05-27 | 2012-12-06 | Novartis Ag | Method of treating vision disorders |
| EP2758073B1 (en) | 2011-09-23 | 2018-10-31 | OncoMed Pharmaceuticals, Inc. | Vegf/dll4 binding agents and uses thereof |
| JP5970734B2 (ja) * | 2012-03-30 | 2016-08-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｎｇ２結合分子 |
| US9292583B2 (en) * | 2012-11-27 | 2016-03-22 | Google Inc. | Method of displaying search results |
-
2012
- 2012-03-29 US US13/433,359 patent/US9527925B2/en active Active
- 2012-03-30 AR ARP120101130A patent/AR085984A1/es active IP Right Grant
- 2012-03-30 EP EP16189545.3A patent/EP3144322A3/en not_active Withdrawn
- 2012-03-30 UY UY0001033998A patent/UY33998A/es unknown
- 2012-03-30 DK DK12711201.9T patent/DK2694546T3/en active
- 2012-03-30 CN CN201280026064.8A patent/CN103562222B/zh active Active
- 2012-03-30 SI SI201230813A patent/SI2694546T1/sl unknown
- 2012-03-30 PT PT127112019T patent/PT2694546T/pt unknown
- 2012-03-30 ES ES12711201.9T patent/ES2606302T3/es active Active
- 2012-03-30 EP EP12711201.9A patent/EP2694546B1/en active Active
- 2012-03-30 SG SG2013070842A patent/SG193561A1/en unknown
- 2012-03-30 MX MX2016000726A patent/MX343440B/es unknown
- 2012-03-30 EA EA201600338A patent/EA036746B1/ru not_active IP Right Cessation
- 2012-03-30 MX MX2013010949A patent/MX337543B/es active IP Right Grant
- 2012-03-30 SG SG10201602373TA patent/SG10201602373TA/en unknown
- 2012-03-30 AU AU2012237234A patent/AU2012237234B2/en not_active Ceased
- 2012-03-30 MA MA36274A patent/MA34979B1/fr unknown
- 2012-03-30 HU HUE12711201A patent/HUE030148T2/en unknown
- 2012-03-30 PH PH1/2013/502044A patent/PH12013502044A1/en unknown
- 2012-03-30 UA UAA201312685A patent/UA114707C2/uk unknown
- 2012-03-30 PE PE2013002134A patent/PE20140448A1/es active IP Right Grant
- 2012-03-30 HR HRP20161689TT patent/HRP20161689T1/hr unknown
- 2012-03-30 AP AP2013007085A patent/AP2013007085A0/xx unknown
- 2012-03-30 BR BR112013025304-5A patent/BR112013025304B1/pt not_active IP Right Cessation
- 2012-03-30 RS RS20161083A patent/RS55361B1/sr unknown
- 2012-03-30 CA CA2827817A patent/CA2827817C/en active Active
- 2012-03-30 PL PL12711201T patent/PL2694546T3/pl unknown
- 2012-03-30 KR KR1020137028120A patent/KR101907572B1/ko active Active
- 2012-03-30 CN CN201610173463.7A patent/CN105820243A/zh active Pending
- 2012-03-30 WO PCT/EP2012/055901 patent/WO2012131078A1/en not_active Ceased
- 2012-03-30 MY MYPI2013003467A patent/MY171007A/en unknown
- 2012-03-30 LT LTEP12711201.9T patent/LT2694546T/lt unknown
- 2012-03-30 EA EA201301108A patent/EA025148B1/ru not_active IP Right Cessation
- 2012-03-30 JP JP2014501665A patent/JP6023786B2/ja active Active
-
2013
- 2013-08-13 IL IL227936A patent/IL227936B/en active IP Right Grant
- 2013-09-12 CL CL2013002623A patent/CL2013002623A1/es unknown
- 2013-09-26 TN TNP2013000390A patent/TN2013000390A1/fr unknown
- 2013-09-27 CO CO13230713A patent/CO6801639A2/es active IP Right Grant
- 2013-10-28 EC ECSP13013001 patent/ECSP13013001A/es unknown
-
2014
- 2014-04-10 HK HK16113827.4A patent/HK1225400A1/zh unknown
-
2016
- 2016-10-07 JP JP2016198857A patent/JP6297657B2/ja active Active
- 2016-11-14 US US15/350,364 patent/US10414828B2/en active Active
- 2016-12-13 CY CY20161101286T patent/CY1118339T1/el unknown
-
2017
- 2017-01-13 AU AU2017200237A patent/AU2017200237B2/en not_active Ceased
-
2019
- 2019-07-18 US US16/515,231 patent/US11161916B2/en active Active
-
2021
- 2021-09-27 US US17/485,561 patent/US20220017642A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085984A1 (es) | Moleculas de union biespecificas que se unen al factor de crecimiento endotelial (vegf) y a la angiopoyetina 2 (ang2) | |
| AR082892A1 (es) | Dominios variables individuales de inmunoglobulina de union al factor de crecimiento endotelial vascular (vegf) | |
| AR078515A1 (es) | Moleculas de union biespecificas de union a vegf (factor de crecimiento endotelial vascular) y a dll4 (ligando 4 de tipo delta) para la terapia anti-angiogenesis | |
| ES2991459T3 (es) | Ligantes de albúmina sérica mejorados | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| MX2019008758A (es) | Anticuerpos anti-cd37 y usos de los mismos. | |
| MX2018015584A (es) | Anticuerpos anti-pd-l1 y usos de los mismos. | |
| BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
| PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
| JP2016513664A5 (es) | ||
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
| RU2017105120A (ru) | Cd3-связывающий домен | |
| FI2691417T4 (fi) | Vasta-aineen Fc-variantteja | |
| PE20121702A1 (es) | Proteinas de enlace cd127 | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| AR091605A1 (es) | Proteinas de union anti-mesotelina | |
| PE20121647A1 (es) | Proteinas terapeuticas de union a dll4 | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |